Improved Survival Benefit with Encorafenib plus Cetuximab plus mFOLFOX6 in First-Line Treatment for Patients with BRAF V600E-mutated mCRC By Ogkologos - June 25, 2025 475 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the BREAKWATER study Source RELATED ARTICLESMORE FROM AUTHOR A Combination of Teclistamab and Daratumumab Prolongs PFS in Patients with Relapsed or Refractory Multiple Myeloma Nivolumab Added to Cisplatin and Radiotherapy Improves DFS in Patients with High-Risk Resected Locally Advanced SCCHN EMA Recommends Granting a Marketing Authorisation for Aumolertinib MOST POPULAR The Recently Leaked Secret to Marijuana News Discovered April 28, 2023 ViPOR Regimen Associated with Durable Remissions in Patients with Specific Molecular... August 7, 2024 New treatment for Waldenstrom’s macroglobulinaemia in England October 1, 2022 Early Evaluation of Nutritional Status Is Needed to Provide Nutritional Support... September 21, 2020 Load more HOT NEWS England: Smoking responsible for twice as many cancers in most deprived... Adjuvant Abemaciclib Combined with Endocrine Therapy Improves IDFS in HR-Positive, HER2−Negative,... How MRI add-ons could accelerate the development of new treatments The award-winning team transforming breast cancer treatment
